Medicinal chemistry – Page 67
-
NewsAntibiotic resistance is a ‘ticking time bomb’
Efforts to tackle the threat will need new thinking, but their may be no easy solutions or short cuts to new drugs
-
Opinion
Is lead linked to violence?
Examining the evidence for the link between lead exposure and violence, Paul Illing finds a cautionary tale
-
Opinion
New antibiotics: what's the hold up?
It’s more a research problem, than a commercial one, says Derek Lowe
-
BusinessUK considers patent rule change for trials
Government to change law that organisations say makes the country less appealing as a location for clinical trials
-
NewsPharmaSea to scour ocean depths for new drugs
Bioprospecting project will investigate marine organisms in the search for new antibiotics and central nervous system therapies
-
Business
Merck resolves Vytorin case for $688m
Investors say the company knew about Enhance trial failure but withheld information
-
CareersToxicologist with pesticides on the brain
Vanessa Fitsanakis’ career in toxicology goes all the way back to the farm where she grew up. Helen Carmichael traces her journey from agriculture to academia
-
Business
GSK commits to AllTrials data disclosure
Company will begin publishing all clinical study reports
-
NewsIndian supreme court’s anger over unregulated clinical trials
Tales of collusion between drug companies and regulators leads court to criticise the government
-
Business
Flu vaccine without the eggs approved
Flublok does not require flu virus or eggs for manufacture
-
Business
EPA focuses on five chemicals
Risk assessments for five chemicals put out for public consultation
-
Business
Illumina investment push
$450 million deal for privately owned US firm Verinata Health, which makes chromosomal tests
-
Business
TB drug milestone for bedaquiline
First TB drug with a new mechanism of action for 40 years wins approval
-
FeatureMaking pain history
From ancient folk remedy to the wonder drug of the early industrial age and beyond. Mike Sutton traces the remarkable history of aspirin
-
Business
Return on drug R&D dropping
The pharma industry is getting less and less return on investment in R&D but trend seems to be bottoming out
-
Business
Drug R&D costs rising
Review from UK consultancy suggests ten-fold increase in per medicine R&D costs over last 30 years
-
Business
Roche and the Tamiflu data
Company position on access to data for antiviral Tamiflu (oseltamivir) tablets could be softening
-
OpinionFull disclosure?
The pharma industry should be more open with its trial data, says Derek Lowe
-
CareersNobel signals for new drugs
Sarah Houlton talks to a company that’s capitalising on the chemistry of communication
-
News
GSK pledge on trials transparency
Pharma giant tackles critics by announcing that it will publish all clinical trials data regardless of the result